np event 2254995 0E193A 1
Sep 30, 2025
- Sep 29, 2026

Update on Long-Acting Nebulizers for Guideline-Based Maintenance Treatments for Patients with COPD

EARNed Credits

0.75

AMA PRA Category 1 CreditsTM

copd lung disease, chronic obstructive pulmonary disorder concept

Overview

This CME program is derived from content presented at the 2025 Eastern Pulmonary Conference. The expert faculty, Dr. Nicola Hanania, will first review the updated 2025 GOLD guidelines for the management of patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) and their implications for guideline-driven care. Following, he will analyze the trial data for LAMA nebulizer therapeutic options to manage COPD. Lastly, Dr. Hanania will discuss clinical strategies to apply guideline-driven long-acting nebulizer treatments for the maintenance of patients with moderate-to-severe COPD.

Who Should Attend

Pulmonologists and other healthcare professionals involved in the treatment and management of patients with COPD

Provided By

Course Faculty

Hanania (1)
Nicola A. Hanania, MD, MS, FRCP(C), FCCP, FERS, AT...
Professor of Medicine
Director, Airways Clinical Research Center
Baylor College of Medicine
Chief, Pulmonary and Critical Care Medicine
Ben Taub Hospital
Houston, TX

Learning Objectives

1

Review the updated 2025 GOLD guidelines for the management of patients with moderate-to-severe COPD and their implications for guideline-driven care

2

Analyze current clinical trial data for LAMA nebulizer therapeutic options to manage COPD

3

Review clinical strategies to apply guideline-driven long-acting nebulizer treatments for the maintenance of patients with moderate-to-severe COPD

Course Agenda

1

Review of Updated 2025 GOLD Guidelines for the Management of Patients with Moderate-to-Severe COPD

2

Pharmacologic and Treatment Benefits of Long-Acting Nebulizer Agents to Improve Airway Function in COPD Patients

3

Clinical Trial Analysis for LAMA Therapeutics for the Management of Patients with Moderate-to-Severe COPD

4

Strategies to Optimize Treatment Plans for the Maintenance Therapy of Patients with Moderate-to-Severe COPD

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Faculty Relationship Identified With:
Nicola A. Hanania, MD Consultant/Advisor: Amgen; AstraZeneca; Chiesi; F. Hoffmann-La Roche Ltd (Genentech); GSK; Regeneron Pharmaceuticals Inc.; Sanofi

Grant/Research Support: Amgen; AstraZeneca; Chiesi; Genentech, Inc.; GSK; Regeneron Pharmaceuticals Inc.; Sanofi

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been supported by an independent educational grant from Viatris Specialty LLC

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Viatris Specialty LLC do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
    2. Complete the Pre-Activity Questions
    3. Read or Review the activity content.
    4. Complete the Post-Activity Test Questions and Evaluation.
    5. Learners who receive a grade of 66% or better on the Post-Activity Test Questions andcomplete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact admin@academiccme.com

np event 2254995 0E193A 1
Sep 30, 2025
- Sep 29, 2026

Update on Long-Acting Nebulizers for Guideline-Based Maintenance Treatments for Patients with COPD

Related Webcast Courses

np document 888746 0E193A 5
Pulmonology
Clinical Update for Non-Cystic Fibrosis Bronchiectasis: Strategies to Manage Exacerbations...
np document 888746 0E193A 5
Pulmonology
Therapeutic Update on COPD with Type 2 Inflammation
np document 888746 0E193A 5
Pulmonology
The Emerging Role of Activin Signaling Inhibitor Therapeutics to Improve Outcomes for Pati...